ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

BON-C1393

Its studies are led by BeOne Medicines.

Furthest: phase 1, since Oct 23, 20261 company-led study, 1 open or runningNext primary completion: Feb 27, 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BeOne Medicines11 open or runningphase 1since Oct 23, 2026Oct 23, 2026Feb 27, 2029phase 1 · NCT07904845

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 23, 2026First study: phase 1 study in Solid TumorsFirst studyNCT07904845 · 90 planned

Ahead

  1. Feb 27, 2029Primary completion: phase 1 study in Solid TumorsNCT07904845

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07904845Solid Tumors1Not yet recruitingFeb 27, 202990

How it is read

Names in the registry

  • “BON-C1393”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.